This large Grant was awarded by the National Institutes of Health-NationalInstitute of Allergy & Infectious Disease [NIH-NIAID], an agency of the U.S.Government. Funding commences October 2007.
Only meritorious HIV/AIDS prevention vaccine candidates are considered toreceive an IPCAVD award. Candidate companies are highly scrutinized and mustsupply substantial positive AIDS vaccine data to support their application.IPCAVD grants are awarded on a competitive basis and are designed to supportlater stage vaccine research, development and human trials.
GeoVax will utilize this funding to further its HIV/AIDS vaccinedevelopment, optimization, production and human clinical trial testingincluding Phase 2 human clinical trials planned for 2008.
Dr. Harriet Robinson, Chief Scientific Advisor for GeoVax, guideddevelopment of the IPCAVD proposal and will lead a major part of its relatedstudies. Dr. Robinson stated, "This grant will allow GeoVax to move forwardour AIDS vaccine evaluation program more efficiently and more rapidly."
"Our selection as a grant recipient is a validation of our vaccinetechnology, scientific program, success in human trials to date and futurestrategies," said GeoVax President/CEO, Don Hildebrand. "This $15 million infunding will support additional AIDS vaccine studies as well as expansion ofour scientific team at GeoVax."
About GeoVax Labs, Inc. (http://www.geovax.com)
GeoVax Labs, Inc. is a biotechnology company, established to develop,manufacture, license and commercialize human vaccines for diseases caused byHIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax'svaccine technology is protected by 20 filed patent applications and issuedpatents.
GeoVax HIV/AIDS vaccines are designed to prevent development of AcquiredImmunodeficiency Disease (AIDS), caused by the virus known as HIV-1, byvaccinating individuals prior to infection with the AIDS virus. In addition,GeoVax AIDS vaccines may be effective as therapeutics (treatment of peopleinfected with AIDS virus). Studies evaluating these vaccines in alreadyHIV/AIDS infected individuals are being planned.
For further information, contact Don Hildebrand or Jennifer Nelms at (404)727-0971 or visit http://www.geovax.com.
Safe Harbor Statement: All statements in this news release, not statementsof historical fact, are forward-looking statements. These statements are basedon expectations and assumptions as of the date of this press release and aresubject to numerous risks and uncertainties which could cause actual resultsto differ materially from those described in the forward-looking statements.Risks and uncertainties include, but are not limited to, whether: GeoVax candevelop and manufacture these vaccines with the desired characteristics in atimely manner, GeoVax's vaccines will be determined to be safe for use inhumans, GeoVax's vaccines will be effective in preventing AIDS in humans, thevaccines will receive the regulatory approvals necessary to be licensed andmarketed, GeoVax can raise the required capital to complete development of itsvaccines, there is development of competitive products that may be moreeffective or easier to use than GeoVax's products, and other factors overwhich GeoVax has no control. GeoVax assumes no obligation to update theseforward-looking statements, and does not intend to do so. Certain mattersdiscussed in this news release are forward-looking statements involvingcertain risks and uncertainties including, without limitations, risks detailedin the Company's Securities and Exchange Commission filings and report.GeoVax DNA
